title: Retisert (Bausch & Lomb/Control Delivery Systems).
abstract: Retisert (Envision TD), a sustained release intraocular implant containing fluocinolone acetonide, has been developed and launched in the US by Bausch & Lomb and Control Delivery Systems for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye.
authors.affiliation: Casey Eye Institute, Oregon Health & Science University, Portland, OR 97201, USA. liml@ohsu.edu
authors.forename: Lyndell L
authors.initials: LL
authors.lastname: Lim
authors.forename: Justine R
authors.initials: JR
authors.lastname: Smith
authors.forename: James T
authors.initials: JT
authors.lastname: Rosenbaum
mesh_terms: D000818:Animals; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D020256:Choroidal Neovascularization / Q000188:drug therapy*; D004195:Disease Models, Animal; D016503:Drug Delivery Systems; D004353:Drug Evaluation, Preclinical; D004343:Drug Implants; D005446:Fluocinolone Acetonide / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D008269:Macular Edema / Q000188:drug therapy*; D010330:Patents as Topic; D016032:Randomized Controlled Trials as Topic; D013329:Structure-Activity Relationship; D015866:Uveitis, Posterior / Q000188:drug therapy*
chemical_list: D000893:Anti-Inflammatory Agents; D004343:Drug Implants; D005446:Fluocinolone Acetonide